Eli Lilly and Company (NYSE: LLY) today released detailed findings from the QWINT-5 phase 3 trial, which compared once-weekly insulin efsitora alfa (efsitora) to daily insulin degludec in adults with…
Oisín Biotechnologies, a privately held company dedicated to addressing age-related diseases, has announced the publication of preclinical data from its follistatin (FST) gene therapy program. The findings, detailed in the…
Novotech, a leading global full-service Contract Research Organization (CRO), has been honored with the 2024 Global Company of the Year Award by Frost & Sullivan. This prestigious accolade highlights Novotech’s…
Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for treating cancer and other serious conditions, has announced the launch of an underwritten public offering of…
CorFlow Therapeutics AG has secured €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners. The funding round also saw participation from 415 Capital, CorFlow’s initial investor…
Ncardia, a leading human iPSC company, has announced the launch of a new panel of ready-to-use assays aimed at streamlining the screening and selection of therapeutic candidates, with a particular…
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, announced its financial results for the third quarter ending July 31, 2024, along with a business update. The company’s lead…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that it will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024, taking place from September 13-17, 2024, in…
Over 187,000 children under ten in central Gaza received the novel oral polio vaccine type 2 (nOPV2) during the first phase of a two-round polio vaccination campaign held from September…
The World Health Organization (WHO) has officially designated the EngAGE Centre for Research in Ageing at Trinity College Dublin as its new Collaborating Centre for Longitudinal Studies on Ageing and…
Ascendis Pharma A/S (Nasdaq: ASND) has released its financial results for the second quarter, which ended on June 30, 2024, alongside a business update. “The recent FDA approval of YORVIPATH…
Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150…